Abstract:BackgroundAdverse Drug Reactions (ADRs) are of great public health concern. FDA-approved drug labeling summarizes ADRs of a drug product mainly in three sections, i.e., Boxed Warning (BW), Warnings and Precautions (WP), and Adverse Reactions (AR), where the severity of ADRs are intended to decrease in the order of BW>WP>AR. Several reported studies have extracted ADRs from labeling documents, but most, if not all, did not discriminate the severity of the ADRs by the different labeling sections. Such a practice could overstate or underestimate the impact of certain ADRs to the public health. In this study, we applied the Medical Dictionary for Regulatory Activities (MedDRA) to drug labeling and systematically analyzed and compared the ADRs from the three labeling sections with a specific emphasis on analyzing serious ADRs presented in BW, which is of most drug safety concern.ResultsThis study investigated New Drug Application (NDA) labeling documents for 1164 single-ingredient drugs using Oracle Text search to extract MedDRA terms. We found that only a small portion of MedDRA Preferred Terms (PTs), 3819 out of 21,920 or 17.42%, were observed in a whole set of documents. In detail, 466/3819 (12.0%) PTs were in BW, 2023/3819 (53.0%) were in WP, and 2961/3819 (77.5%) were in AR sections. We also found a higher overlap of top 20 occurring BW PTs with WP sections compared to AR sections. Within the MedDRA System Organ Class levels, serious ADRs (sADRs) from BW were prevalent in Nervous System disorders and Vascular disorders. A Hierarchical Cluster Analysis (HCA) revealed that drugs within the same therapeutic category shared the same ADR patterns in BW (e.g., nervous system drug class is highly associated with drug abuse terms such as dependence, substance abuse, and respiratory depression).ConclusionsThis study demonstrated that combining MedDRA standard terminologies with data mining techniques facilitated computer-aided ADR analysis of drug labeling. We also highlighted the importance of labeling sections that differ in seriousness and application in drug safety. Using sADRs primarily related to BW sections, we illustrated a prototype approach for computer-aided ADR monitoring and studies which can be applied to other public health documents.

MetaADEDB 2.0: a Comprehensive Database on Adverse Drug Events

Adverse drug events: database construction and in silico prediction.

Study of Serious Adverse Drug Reactions Using FDA-approved Drug Labeling and MedDRA

Detecting Adverse Drug Event Signals from a Clinical CaseBase.

Identification of Adverse Drug Events in Chinese Clinical Narrative Text

A method for systematic discovery of adverse drug events from clinical notes.

Adme-Ap: A Database of Adme Associated Proteins

CT-ADE: An Evaluation Benchmark for Adverse Drug Event Prediction from Clinical Trial Results

ODAE: Ontology-based Systematic Representation and Analysis of Drug Adverse Events and Its Usage in Study of Adverse Events Given Different Patient Age and Disease Conditions.

mtADENet: A novel interpretable method integrating multiple types of network-based inference approaches for prediction of adverse drug events

ADEPt, a semantically-enriched pipeline for extracting adverse drug events from free-text electronic health records

Development of an adverse drug event network to predict drug toxicity

ADReCS: an Ontology Database for Aiding Standardization and Hierarchical Classification of Adverse Drug Reaction Terms

DrugMAP 2.0: molecular atlas and pharma-information of all drugs

OnSIDES (ON-label SIDE effectS resource) Database : Extracting Adverse Drug Events from Drug Labels using Natural Language Processing Models

BioDEX: Large-Scale Biomedical Adverse Drug Event Extraction for Real-World Pharmacovigilance

INTEDE 2.0: the Metabolic Roadmap of Drugs.

Meta-analysis of Censored Adverse Events

Mining Real-World Big Data to Characterize Adverse Drug Reaction Quantitatively: Mixed Methods Study

Study and Practice of Chinese Drug Adverse Effect Database Creation

admetSAR3.0: a comprehensive platform for exploration, prediction and optimization of chemical ADMET properties